NICEVIVA
MONOGRAPH SPEC LATEST 2026

Lycium barbarum (Goji)

TRADITIONAL ASIAN · Evidence Monograph

Lycium barbarum (Goji) is an evidence-graded traditional asian monograph evaluated across 30 peer-reviewed PubMed studies (1 meta-analyses, 3 systematic reviews, and 4 randomized controlled trials, encompassing n = 1,749 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 30 Studies
Meta-Analyses · Reviews 1 Meta · 3 Systematic Reviews
Randomized Trials (RCT) 4 RCTs (5 Double-Blind)
Cumulative Participants n = 1,749
Reported Trial Dosages 400 mg · 28 g · 6 mg
Trial Duration Range 90 days · 15 days · 52 weeks
Reading Time ~15 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 30 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (400 mg · 28 g · 6 mg) over a structured 90 days evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
With Breakfast or Lunch
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary traditional asian clinical efficacy (30 PubMed studies)
Quantitative biomarker & outcome analysis (10 studies with effect-size/sample data)
Randomized controlled trial verification (4 RCTs · 5 double-blind)
Systematic review & meta-analysis synthesis (1 meta-analyses · 3 reviews)
01

What Is Lycium barbarum (Goji) & Why Does Form Matter?

Lycium barbarum (Goji) is classified under TRADITIONAL ASIAN and has been investigated across 30 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (400 mg, 28 g, 6 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Lycium barbarum (Goji) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (4 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Lycium barbarum (Goji) acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Lycium barbarum (Goji) an overall evidence rating of GRADE High (4.0 / 4.0) based on 30 PubMed studies: 1 meta-analyses, 3 systematic reviews, and 4 randomized controlled trials (5 double-blind, n = 1,749 total participants).

Representative peer-reviewed findings include: • PMID:34213407 (2022) — "The Effect of Lycium Barbarum Polysaccharide on the Glucose and Lipid Metabolism: A Systematic Review and Meta-Analysis." (The present study provided a better understanding of current research status and suggested that LBP could play potential role in prevention and therapy for non-communicable chronic diseases, and more scientific evidence are required in the future.Key teaching pointsGoji berry and) • PMID:29557436 (2018) — "Effects of superfoods on risk factors of metabolic syndrome: a systematic review of human intervention trials." (Furthermore, conclusions may be different if other health benefits are considered.) • PMID:28629116 (2017) — "Systematic Review of Chemical Constituents in the Genus Lycium (Solanaceae)." (This comprehensive study could lay the foundation for further research on the Lycium genus.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 400 mg · 28 g · 6 mg · 4 mg over 90 days · 15 days · 52 weeks · 3 months. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Lycium barbarum (Goji), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (400 mg · 28 g · 6 mg) and re-evaluate efficacy after 90 days.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (30 Studies) · 10 Quantitative Analyses

01
META-ANALYSIS Journal of the American Nutrition Association (2022) PMID: 34213407 ↗
The Effect of Lycium Barbarum Polysaccharide on the Glucose and Lipid Metabolism: A Systematic Review and Meta-Analysis.
Clinical Trial Synthesis 2022 Meta-Analysis published in Journal of the American Nutrition Association; statistical significance reported at p = 0.05. Key conclusion: The present study provided a better understanding of current research status and suggested that LBP could play potential role in prevention and therapy for non-communicable chronic diseases, and more scientific evidence are required in the future.Key teaching pointsGoji berry and
View Original PubMed Abstract ↓

Goji berry has been used in China more than 2,000 years as a traditional medicinal herb and food supplement. Lycium barbarum polysaccharide (LBP), the chief active component in goji berry, has been used to treat hypertension, atherosclerosis and other cardiovascular diseases in Chinese traditional medicine. However, the underlying effects of LBP- mediated activity in blood glucose and lipid metabolism remain poorly understood. The present study aims to apply the meta-analysis to explore the healthy effects of LBP. Eligible studies published up to November 15, 2020, were searched and identified from CNKI, Pubmed, Web of Science, Cocharane library detabases. A total of 315 publications were retrieved and 7 articles were included. The STATA (version 11.0) was applied to process the meta-analysis. The pooled estimate showed that daily consumption of LBP played significant effects on regulating serum triglyceride (TG), fasting blood glucose, and low-density lipoprotein (LDL) and high-density lipoprotein (HDL) concentrations (p < 0.05), while it was effect-free on the total cholesterol (TC). The present study provided a better understanding of current research status and suggested that LBP could play potential role in prevention and therapy for non-communicable chronic diseases, and more scientific evidence are required in the future.Key teaching pointsGoji berry and LBP, its main biologically active ingredient, have a wide range of health promotion effects.The supplement of LBP may played significant effects on regulating serum TG, HDL, LDL and FBG concentrations.Goji may serve as a potential drug to prevent and treat chronic non-communicable diseases in the future.Healthy dietary patterns containing goji berries will be a new choice for consumers in the future.

02
SYSTEMATIC REVIEW Food & function (2018) PMID: 29557436 ↗
Effects of superfoods on risk factors of metabolic syndrome: a systematic review of human intervention trials.
Clinical Trial Synthesis 2018 Systematic Review published in Food & function. Key conclusion: Furthermore, conclusions may be different if other health benefits are considered.
View Original PubMed Abstract ↓

Functional foods can be effective in the prevention of metabolic syndrome and subsequently the onset of cardiovascular diseases and type II diabetes mellitus. More recently, however, another term was introduced to describe foods with additional health benefits: "superfoods", for which, to date, no generally accepted definition exists. Nonetheless, their consumption might contribute to the prevention of metabolic syndrome, for example due to the presence of potentially bioactive compounds. This review provides an overview of controlled human intervention studies with foods described as "superfoods" and their effects on metabolic syndrome parameters. First, an Internet search was performed to identify foods described as superfoods. For these superfoods, controlled human intervention trials were identified until April 2017 investigating the effects of superfood consumption on metabolic syndrome parameters: waist circumference or BMI, blood pressure, or concentrations of HDL cholesterol, triacylglycerol or glucose. Seventeen superfoods were identified, including a total of 113 intervention trials: blueberries (8 studies), cranberries (8), goji berries (3), strawberries (7), chili peppers (3), garlic (21), ginger (10), chia seed (5), flaxseed (22), quinoa (1), cocoa (16), maca (1), spirulina (7), wheatgrass (1), acai berries (0), hemp seed (0) and bee pollen (0). Overall, only limited evidence was found for the effects of the foods described as superfoods on metabolic syndrome parameters, since results were not consistent or the number of controlled intervention trials was limited. The inconsistencies might have been related to intervention-related factors, such as duration or dose. Furthermore, conclusions may be different if other health benefits are considered.

03
SYSTEMATIC REVIEW Molecules (Basel, Switzerland) (2017) PMID: 28629116 ↗
Systematic Review of Chemical Constituents in the Genus Lycium (Solanaceae).
Clinical Trial Synthesis 2017 Systematic Review published in Molecules (Basel, Switzerland). Key conclusion: This comprehensive study could lay the foundation for further research on the Lycium genus.
View Original PubMed Abstract ↓

The Lycium genus is widely used as a traditional Chinese medicine and functional food. Many of the chemical constituents of the genus Lycium were reported previously. In this review, in addition to the polysaccharides, we have enumerated 355 chemical constituents and nutrients, including 22 glycerogalactolipids, 29 phenylpropanoids, 10 coumarins, 13 lignans, 32 flavonoids, 37 amides, 72 alkaloids, four anthraquinones, 32 organic acids, 39 terpenoids, 57 sterols, steroids, and their derivatives, five peptides and three other constituents. This comprehensive study could lay the foundation for further research on the Lycium genus.

04
SYSTEMATIC REVIEW Journal of dietary supplements (2015) PMID: 24806435 ↗
An Evidence-Based Systematic Review of Goji (Lycium spp.) by the Natural Standard Research Collaboration.
Clinical Trial Synthesis 2015 Systematic Review published in Journal of dietary supplements. Key conclusion: This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.
View Original PubMed Abstract ↓

An evidence-based systematic review of goji (Lycium spp.) by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.

05
RANDOMIZED TRIAL (RCT) Tissue & cell (2026) PMID: 41032943 ↗
The effects of Lycium barbarum polysaccharide on oxidative stress and sperm health in varicocele patients: A randomized clinical trial.
Clinical Trial Synthesis 2026 Randomized Controlled Trial (RCT) published in Tissue & cell involving n = 40 participants; statistical significance reported at p = 0.05. Key conclusion: In conclusion, the results suggest that Lycium barbarum polysaccharide has a positive effect on oxidative stress and sperm health.
View Original PubMed Abstract ↓

Varicocele is an abnormal enlargement of scrotal veins, significantly contributing to male infertility. The plant Lycium barbarum, known for its high antioxidant properties, may enhance fertility quality. This study examines the protective and antioxidant effects of Lycium barbarum polysaccharide on sperm health in patients with varicocele. In a double-blind clinical trial conducted in 2022 at Afzalipoor Hospital in Kerman, 80 patients with varicocele were randomly assigned to either an intervention group (n = 40) or a control group (n = 40). After collecting demographic, blood, and semen samples, the intervention group received 400 mg of Lycium barbarum extract orally for two months, while the control group received a placebo. Blood and semen samples were re-evaluated 90 days post-treatment for markers such as Superoxide dismutase, Glutathione peroxidase, Malondialdehyde, and Testosterone, as well as sperm health parameters. Before treatment, the Mann-Whitney test showed no significant difference between the groups (P < 0.05). The intervention group exhibited effective enhancement in antioxidant enzyme activity (Superoxide dismutase, Glutathione peroxidase). The intervention with Lycium barbarum resulted in a significant decrease in Malondialdehyde (MDA) levels, indicating a reduction in oxidative stress. Significant improvements in Testosterone level and sperm count, motility, and morphology, indicating the intervention's positive impact on male fertility indicators, excluding semen volume (P < 0.05). The volume of semen following the intervention with Lycium barbarum showed a slight increase post-intervention. In conclusion, the results suggest that Lycium barbarum polysaccharide has a positive effect on oxidative stress and sperm health. Further research with larger sample sizes is recommended to enhance the generalizability of these findings.

06
RANDOMIZED TRIAL (RCT) F1000Research (2023) PMID: 39640061 ↗
Efficacy of Lycium barbarum (Goji berry) mouthwash for managing periodontitis: a randomized clinical trial.
Clinical Trial Synthesis 2023 Randomized Controlled Trial (RCT) published in F1000Research. Key conclusion: Goji berry mouthwash was more effective than chlorhexidine in increasing the antioxidant levels in saliva.
View Original PubMed Abstract ↓

BACKGROUND: Removal of the microbial deposits (plaque and calculus) by performing effective scaling and root planing (SRP) is the fundamental step for managing periodontal disease (gingivitis and periodontitis). Various adjuncts in the form of mouthwash, gels, and toothpaste are also being used as adjuncts to SRP for managing periodontitis. Recently, Lycium barbarum ( L. barbarum), commonly known as goji berry or wolfberry, has gained popularity for managing chronic inflammatory and infectious diseases. However, its efficacy in managing periodontitis has never been explored. Hence the present study aims to evaluate the efficacy of goji berry mouthwash compared to chlorhexidine mouthwash for managing periodontitis. METHODS: 60 adult participants were divided randomly using computer-generated random sequences into two groups (case group: L. barbarum mouthwash (Males: 16; Female: 14); control group: 0.2% chlorhexidine gluconate mouthwash (Males: 14; Females: 16)). The changes in the gingival index (Gi), plaque index (Pi), bleeding on probing (BOP), clinical attachment loss (CAL), probing pocket depth (PPD), microbial load, and antioxidant levels (protein thiol) in saliva were noted at the baseline, at 15 days and one month. RESULTS: A significant reduction in the mean PPD, Pi, BOP, and Gi was seen from baseline to one month in both the control (P-value=0.006, 0.027, 0.000, and 0.036 respectively) and test groups (P-value=0.035, 0.000, 0.034, and 0.000 respectively). However, the antioxidant levels (protein thiol) in saliva were significantly increased only in the test group. CONCLUSION: Goji berry mouthwash along with SRP reduced the Gi, Pi, BOP, and PPD in patients with periodontitis. However, no statistically significant difference was noted between the use of goji berry and chlorhexidine mouthwash. Goji berry mouthwash was more effective than chlorhexidine in increasing the antioxidant levels in saliva. Copyright: © 2024 Sanghavi A et al.

07
RANDOMIZED TRIAL (RCT) Nutrients (2021) PMID: 34959963 ↗
Goji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults: A Randomized Pilot Trial.
Clinical Trial Synthesis 2021 Randomized Controlled Trial (RCT) published in Nutrients involving n = 27 participants; statistical significance reported at p = 0.029. Key conclusion: Regular intake of goji berries in a healthy middle-aged population increases MPOD may help prevent or delay the development of AMD.
View Original PubMed Abstract ↓

Age-related macular degeneration (AMD) is the third leading cause of blindness worldwide. Macular pigment optical density (MPOD), a biomarker for AMD, is a non-invasive measure to assess risk. The macula xanthophyll pigments lutein (L) and zeaxanthin (Z) protect against blue light and provide oxidant defense, which can be indexed by MPOD. This study examined the effects of Z-rich goji berry intake on MPOD and skin carotenoids in healthy individuals. A randomized, unmasked, parallel-arm study was conducted with 27 participants, aged 45-65, who consumed either 28 g of goji berries or a supplement containing 6 mg L and 4 mg Z (LZ), five times weekly for 90 days. After 90 days, MPOD was significantly increased in the goji berry group at 0.25 and 1.75 retinal eccentricities (p = 0.029 and p = 0.044, respectively), while no changes were noted in the LZ group. Skin carotenoids were significantly increased in the goji berry group at day 45 (p = 0.025) and day 90 (p = 0.006), but not in the LZ group. Regular intake of goji berries in a healthy middle-aged population increases MPOD may help prevent or delay the development of AMD.

08
CLINICAL STUDY Journal of ethnopharmacology (2019) PMID: 30877066 ↗
Delay of cone degeneration in retinitis pigmentosa using a 12-month treatment with Lycium barbarum supplement.
Clinical Trial Synthesis 2019 Clinical Study published in Journal of ethnopharmacology; statistical significance reported at p = 0.001. Key conclusion: CONCLUSIONS: LB supplement provides a neuroprotective effect for the retina and could help delay or minimize cone degeneration in RP.
View Original PubMed Abstract ↓

ETHNOPHARMACOLOGICAL RELEVANCE: Lycium barbarum L. (also known as "Goji berry"), a traditional Chinese herbal medicine, has been a common herb in the traditional Chinese pharmacopoeia for centuries. The main active component is the Lycium barbarum polysaccharides and its antioxidative effect has been widely shown to provide neuroprotection to the eye, and it would, therefore, be interesting to determine if Lycium barbarum help delay vision deterioration in patients with retinitis pigmentosa. AIM OF THE STUDY: Cone rescue is a potential method for delaying deterioration of visual function in Retinitis pigmentosa (RP). This study aimed to investigate the treatment effect of Lycium barbarum L. (LB) supplement on retinal functions and structure in RP patients after a 12-month intervention trial. METHODS: The investigation was a double-masked and placebo-controlled clinical study. Each of forty-two RP subjects who completed the 12-month intervention (23 and 19 in the treatment and placebo groups respectively) received a daily supply of LB or placebo granules for oral administration. The primary outcome was change of best corrected visual acuity (VA) (90% and 10% contrast) from the baseline to the end of treatment. The secondary outcomes were sensitivity changes of the central visual field, amplitude of full-field electroretinogram (ffERG) (including scotopic maximal response and photopic cone response), and average macular thickness. RESULTS: The compliance rates for both groups exceeded 80%. There were no deteriorations of either 90% or 10% contrast VA in the LB group compared with the placebo group (p = 0.001). A thinning of macular layer was observed in the placebo group, which was not observed in the LB group (p = 0.008). However, no significant differences were found in the sensitivity of visual field or in any parameters of ffERG between the two groups. No significant adverse effects were reported in the treatment group. CONCLUSIONS: LB supplement provides a neuroprotective effect for the retina and could help delay or minimize cone degeneration in RP. CLASSIFICATIONS: Clinical Studies (1.05). TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT02244996.

09
CLINICAL STUDY Journal of atherosclerosis and thrombosis (2016) PMID: 25891210 ↗
Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.
Clinical Trial Synthesis 2016 Randomized Controlled Trial (RCT) published in Journal of atherosclerosis and thrombosis. Key conclusion: CONCLUSIONS: Pitavastatin significantly reduced the LDL-C levels and was well tolerated when administered at usual adult doses in 14 male children 10-15 years of age with heterozygous FH.
View Original PubMed Abstract ↓

AIM: The purpose of this study was to evaluate the efficacy and safety of LIVALO tablets (pitavastatin) in Japanese male children with heterozygous familial hypercholesterolemia (FH). METHODS: A multicenter, randomized, double-blind, parallel study was conducted in 14 male children 10-15 years of age with heterozygous FH. Pitavastatin (1 mg/day or 2 mg/day) was administered orally for 52 weeks.The primary endpoint was the percent change in the LDL-cholesterol (LDL-C) concentrations from baseline to endpoint (repeated measures ANCOVA at Weeks 8 and 12). Secondary endpoints included the percentage of patients who achieved the target LDL-C concentration and percent changes in the levels of lipoprotein and lipid parameters at the visit performed at 52 weeks. RESULTS: The percent change in LDL-C from baseline (mean 258 mg/dL for all patients) to the endpoint was -27.3% (95%CI; -34.0, -20.5) and -34.3% (95%CI; -41.0, -27.5) in the patients receiving 1 mg and 2 mg of pitavastatin, respectively. Stable reductions in the total cholesterol (TC), non-HDL cholesterol (non-HDL-C), apolipoprotein B (Apo-B) and LDL-C levels and non-HDL-C/HDL-C and Apo-B/Apo-A1 ratios were observed up to 52 weeks in both groups. One patient in each dose group (14%) reached the treatment target level of 130 mg/dL.Adverse events were observed in seven (100%) patients receiving 1 mg and five (71%) patients receiving 2 mg of pitavastatin, although none were considered related to the study treatment. One patient in the 1 mg group reported a musculoskeletal AE; however, it was attributed to recent excessive exercise. CONCLUSIONS: Pitavastatin significantly reduced the LDL-C levels and was well tolerated when administered at usual adult doses in 14 male children 10-15 years of age with heterozygous FH. Pitavastatin is a promising therapeutic agent for pediatric dyslipidemia with few safety concerns.

10
CLINICAL STUDY Medicinal chemistry (Shariqah (United Arab Emirates)) (2015) PMID: 25381995 ↗
Practical Application of Antidiabetic Efficacy of Lycium barbarum Polysaccharide in Patients with Type 2 Diabetes.
Clinical Trial Synthesis 2015 Randomized Controlled Trial (RCT) published in Medicinal chemistry (Shariqah (United Arab Emirates)) involving n = 67 participants. Key conclusion: LBP also increased HDL levels in patients with type 2 diabetes.
View Original PubMed Abstract ↓

Lycium barbarum polysaccharide (LBP) has traditionally been used in Chinese medicine as a chief ingredient of Lycium barbarum (wolf berry/goji berry) for the treatment of various diseases with the symptoms of frequent drinking and urination. This study was conducted as a randomized, controlled clinical trial. A total of 67 patients with type 2 diabetes (30 in control group and 37 in LBP group) were enrolled in this prospective, randomized, double-blind study (administration at 300 mg/day body weight). In order to observe the hypoglycemic and lipid-lowering activity of LBP in patients with type 2 diabetes after dinner, various tests were conducted between control and LBP intervention groups in 3 months. Although, the study had small sample size and short follow-up, significant findings were observed. The results of our study indicated a remarkable protective effect of LBP in patients with type 2 diabetes. Serum glucose was found to be significantly decreased and insulinogenic index increased during OMTT after 3 months administration of LBP. LBP also increased HDL levels in patients with type 2 diabetes. It showed more obvious hypoglycemic efficacy for those people who did not take any hypoglycemic medicine compared to patients taking hypoglycemic medicines. This study showed LBP to be a good potential treatment aided-agent for type 2 diabetes.

RELATED MONOGRAPHS

Related Monographs in This Category